On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging Hangzhou DAC’s CPT113 linker payload technology.Also Read: Cancer ...

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC   Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001 ...

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.71 per share when it actually produced a loss of $0.54, delivering a surprise of 23.94%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Aadi Bioscience, which belongs to th ...

PRESS RELEASE Exhibit 99.1 Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth Aadi continues to focus on FYARRO commercial business and comprehensive strategic review to maximize shareholder value LOS ANGELES, CA, November 6, 2024 – Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corp ...

LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or ...

PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO® commercial business for its approved indication, PEComa, and conduct a comprehensive strategic review to maximize shareholder value To further preserve cash position, Aadi will adjust ongoing Phase 2 trials and reduce R&D headcount by 80%, thereby extending cash runway into at least 2H 2026LOS ANGELES, Aug. 20, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASD ...

Aadi Bioscience, Inc. (NASDAQ:AADI) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants David Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience Inc. Second Quarte ...

Q2 2024 Results Presentation August 7, 2024 Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-3856 ...